[Antihypertensive efficacy, tolerance and safety of lisinopril (sinopril) and captopril (capoten) in patients with mild and moderate arterial hypertension]. / Antigipertenzivnaia éffektivnost', perenosimost' i bezopasnost' lizinoprila (sinoprida) i kaptoprila (kapotena) u bol'nykh miagkoi i umerennoi arterial'noi gipertoniei.

AIM: To compare effectiveness, tolerance and safety of two inhibitors of angiotensin-converting enzyme--sinopril (lisinopril) and capoten (captopril)--in outpatient treatment of patients with mild and moderate hypertension. MATERIALS AND METHODS: The patients were randomly assigned to sinopril or capoten groups. Sinopril was given in daily dose 10-40 mg, capoten--in daily dose 25-100 mg for 8 weeks. In insufficient antihypertensive effect of monotherapy on day 21, hydrochlortiaside was added. The effect was judged by influence on arterial pressure, heart rate, tolerance (questionnaire), safety (blood count, urinalysis. ECG). RESULTS: Sinopril produced good antihypertensive effect in 73.3% of patients (monotherapy) and 88.9% (combined therapy). For capoten it was 68.9 and 82.2%, respectively. The time of the beginning of the antihypertensive effect (4-20 days after the start of the treatment) for sinopril and copoten differed insignificantly and depended on hypertension severity (mild or moderate). Tolerance of both drugs was good, serious side effects were absent. Discontinuation of the drugs was needed in 4% of patients, only. No negative action on bioelectric activity of the heart, clinical and biochemical blood indices were found. CONCLUSION: Sinopril and capoten demonstrate high antihypertensive activity.

[Residual hypertension after removal of a pheochromocytoma (morphologic study of the kidneys)]. / Rezidual'naia gipertoniia posle udaleniia feokhromotsitomy (morfologicheskoe issledovanie pochek).

Renal parenchyma, and the juxtaglomerular apparatus in particular, was studied in 23 patients with verified diagnosis of pheochromocytoma. Intraoperative renal biopsy was performed in 21 cases, and kidneys obtained at nephrectomy or autopsy were examined in 2 cases. Twenty-one patients were examined following the removal of pheochromocytoma (2 patients died). Arterial BP returned to normal in 86.4%, and residual hypertension due to continuous hyperfunction of the juxtaglomerular apparatus in the presence of hypertensive angiosclerosis was recorded in 13.6%. Tubular epithelial atrophy of varying markedness, associated with renal ischemia, was detected in all cases. The pathogenetic contribution of the renin-angiotensin system to pre- and postoperative hypertension in pheochromocytoma patients is discussed.

[Pheochromocytoma with infarction-like changes in the heart and marked proteinuria]. / Feokhromotsitoma s infarktopodobnymi izmeneniiami serdtsa i vyrazhennoi proteinuriei.

The authors provide a clinical example illustrating difficulties in the diagnosis of pheochromocytoma in a patient with infarction-like lesions in the heart, marked proteinuria, and diverse symptomatics due to excess catecholamine secretion by the tumor.

[The heart in malignant arterial hypertension: comparison of the results of morphological and electrocardiographic studies]. / Serdtse pri zlokachestvennoi arterial'noi gipertonii: sopostavlenie rezul'tatov morfologicheskogo i elektrokardiograficheskogo issledovaniia.

The electrocardiographic changes in patients with malignant arterial hypertension verified by the results of the pathoanatomic heart study have been analysed. The authors suggest a new classification of coronary arteries involvement in malignant hypertension. The informative value of Sokolov-Layon's criteria in malignant arterial hypertension is discussed.

[Effect of adrenergic beta-receptor blockaders on thrombocyte aggregation capacity in arterial hypertension]. / Vliianie blokatorov beta-adrenergicheskikh retseptorov na agregatsionnuiu sposobnost' trombotsitov u bol'nykh arterial'noi gipertoniei.

The study of the aggregation capacity of platelets and the coagulation system of the blood by thromboelastography was undertaken in 36 patients with different forms of arterial hypertension. In 11 patients receiving obsidan these tests were repeated every 4-20 days. In patients with hypertension and pyelonephritis the aggregation capacity of platelets was enhanced, and in patients with glomerulonephritis it was not materially changed. All patients showed a shift in the food coagulation system toward moderate hypercoagulation, which did not change much with obsidan. A relationship between the blood pressure (BP) level and the functional properties of platelets was recorded. There was a simultaneous tendency to the decrease of BP and the inhibition of the aggregation capacity of platelets. Obsidan produces antiaggregation effect related to the decreased stability of platelet aggregates.